Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention.
https://doi.org/10.14341/DM7674
Abstract
Aim. Тo determine the serum level of EMAP-II in type 1 diabetic patients with microangyopathy and arterial hypertention.
Materials and methods We examined 23 type 1 diabetic patient with microangyopathy and arterial hypertention, 10 type 1 diabetic patient with microangyopathy without hypertention and 28 control subjects. Serum levels of EMAP-II were determined by immunoenzyme assay. The data were presented as means±SD.
Results. We found an increased serum level of EMAP-II in type 1 diabetic patients with microangyopathy and arterial hypertention compared to control group (5,23±1,66 ng/ml and 1,25±0,76 ng/ml respectively, р<0,01), and in type 1 diabetic patients with microangyopathy and arterial hypertension compared to group without hypertension (5,23±1,66 ng/ml and 3,63±1,9 ng/ml respectively, р<0,01). Also, the level of EMAP-II correlated with key markers of carbohydrate and lipid metabolism, inverse correlated with endothelium-dependent dilatation (p<0,05).
Conclusion. The revealed change of EMAP-II could reflect an endothelial dysfunction in patients with type 1 diabetes with microangyopathy and arterial hypertension. Arterial hypertension, hyperglycemia, dyslipidemia appears to be significant factor to contributing elevation of EMAP-II.
Keywords: Endothelial monocyte activating polypeptide II, endothelial dysfunction, type 1 diabetes, arterial hypertension.
About the Authors
Liliya A. Mogylnytska
Khmelnitsky regional hospital
Ukraine
MD, PhD
Competing Interests: No conflict of interest
Ukraine
MD, PhD
Competing Interests: No conflict of interest
Boris N. Mankovsky
National Medical Academy for Postgraduate Education
Ukraine
MD, PhD, Professor, correspondence fellow of the National Academy of Medical Sciences of Ukraine
Competing Interests: No conflict of interest
Ukraine
MD, PhD, Professor, correspondence fellow of the National Academy of Medical Sciences of Ukraine
Competing Interests: No conflict of interest
References
1. Danaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants. The Lancet. 2011;377(9765):568-577. doi: 10.1016/s0140-6736(10)62036-3
2. American Diabetes A. Standards of medical care in diabetes--2014. Diabetes Care. 2014;37 Suppl 1:S14-80. doi: 10.2337/dc14-S014
3. European Stroke Organisation, Tendera M, Aboyans V, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J.2011;32(22):2851-2906. doi: 10.1093/eurheartj/ehr211
4. Tooke JE. Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes. J Diabetes Complications. 2000;14(4):197-200. doi: 10.1016/s1056-8727(00)00083-0
5. Mogylnytska LA. Endothelial monocyte-activating polypeptide-II: properties, functions, and pathogenetic significance. Fiziol Zh. 2015;61(1):102-11.
6. Wajchenberg BL, Rassi N, Feitosa ACR, et al. Doença cardiovascular no diabetes melito tipo 1. Arq Bras Endocrinol Metabol. 2008;52(2):387-397. doi: 10.1590/s0004-27302008000200027
7. Giannini C, Mohn A, Chiarelli F, Kelnar CJ. Macrovascular angiopathy in children and adolescents with type 1 diabetes. Diabetes Metab Res Rev. 2011;27(5):436-460. doi: 10.1002/dmrr.1195
8. Mintz GS, Maehara A. Serial Intravascular Ultrasound Assessment of Atherosclerosis Progression and Regression. Circ J. 2009;73(9):1557-1560. doi: 10.1253/circj.CJ-09-0475
9. Hypertension EETFftMoA. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31(10):1925-1938. doi: 10.1097/HJH.0b013e328364ca4c
10. Kohner EM, Porta M. Protocols for screening and treatment of diabetic retinopathy in Europe. Eur J Ophthalmol. 1991;1(1):45-54.
11. Mogensen CE. Introduction: Diabetes mellitus and the kidney. Kidney Int. 1982;21(5):673-675. doi: 10.1038/ki.1982.79
12. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. The Lancet. 1992;340(8828):1111-1115. doi: 10.1016/0140-6736(92)93147-f
13. Tocci G, Ferrucci A, Guida P, et al. An analysis of the management of cardiovascular risk factors in routine clinical practice in Italy: an overview of the main findings of the EFFECTUS study. High Blood Press Cardiovasc Prev. 2011;18(1):19-30. doi: 10.2165/11588040-000000000-00000
14. Cockcroft J, Mancia G. Vascular aging: shifting the paradigm of risk assessment and reduction in hypertension. J Hypertens. 2012;30 Suppl:S1-2. doi: 10.1097/HJH.0b013e328353e4ec
15. Giannini C, Mohn A, Chiarelli F, Kelnar CJ. Macrovascular angiopathy in children and adolescents with type 1 diabetes. Diabetes Metab Res Rev. 2011;27(5):436-460. doi: 10.1002/dmrr.1195
16. Mintz GS, Maehara A. Serial Intravascular Ultrasound Assessment of Atherosclerosis Progression and Regression. Circulation Journal. 2009;73(9):1557-1560. doi: 10.1253/circj.CJ-09-0475
17. Mohyl’nyts’ka LA. Serum levels of endothelial monocyte-activating polypeptide-II in type 2 diabetes mellitus. Fiziol Zh. 2014;60(1):84-90.
18. Adly AA, Ismail EA, Tawfik LM, et al. Endothelial monocyte activating polypeptide II in children and adolescents with type 1 diabetes mellitus: Relation to micro-vascular complications. Cytokine.2015;76(2):156-162. doi: 10.1016/j.cyto.2015.06.006
19. Burns SF, Lee S, Bacha F, et al. Pre-diabetes in overweight youth and early atherogenic risk. Metabolism. 2014;63(12):1528-1535. doi: 10.1016/j.metabol.2014.08.008
Supplementary files
Review
For citations:
Mogylnytska L.A., Mankovsky B.N. Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention. Diabetes mellitus. 2016;19(4):309-314. (In Russ.) https://doi.org/10.14341/DM7674
Views:
510
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
